# Treatment Options for Esophageal Cancer
The treatment of esophageal cancer is determined by the stage of the cancer, the type of cells that make up the tumor, the patient's overall health, and what the patient can manage. Doctors usually use a combination of treatments. Below is an overview of the standard approaches per disease stage.
Early stage (in situ and low-invasive tumors)
For very early cancer that is only in the surface of the esophagus (in situ), or tumors that have minimally invaded deeply, endoscopic treatment may be sufficient.
**Endoscopic Submucosal Dissection (ESD)**
ProveniIncluded in official guidelines, or approved by EMA or FDA
This is a minimally invasive technique in which the tumor is removed step by step from the mucous layer under the guidance of an endoscope (a thin tube with a camera). The doctor cuts away the healthy tissue around the tumor and removes it completely. This approach preserves much normal esophageal tissue and avoids major surgery. Side effects can include bleeding and perforation (rupture) of the esophageal wall; these occur rarely and are usually detected and treated immediately. Some centers combine this procedure with injection of the patient's own fat cells around the suture to prevent scarring of the esophagus; this is still being studied.
**Endoscopic Mucosal Resection (EMR)**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Similar to ESD, but uses different equipment and works faster. Suitable for slightly larger early-stage tumors. The same risks as ESD, usually minor.
Locally limited cancer (without metastases)
This is cancer that has grown into the muscle layers or surrounding tissues, but has not yet spread to other parts of the body. The standard treatment is usually a combination of chemotherapy and radiation, followed by surgery. Sometimes surgery comes first.
**Neoadjuvant Chemoradiotherapy (chemotherapy + radiation before surgery)**
ProveniIncluded in official guidelines, or approved by EMA or FDA
The patient first receives chemotherapy drugs (usually platinum and fluorouracil) while the tumor and surrounding lymph nodes are simultaneously treated with external radiation. This shrinks the tumor before it is removed. After completion of this regimen, surgery usually follows. This approach improves survival chances compared to radiation alone or chemotherapy alone. Side effects of chemotherapy include fatigue, nausea, anemia, and immune-related infections. Radiation can cause a burning sensation in the esophagus, difficulty swallowing, and fatigue. Both forms of treatment are burdensome on the body.
**Neoadjuvant Chemoimmunotherapy**
ResearchediPositive results in clinical studies, not yet standard treatment
This is a newer approach in which chemotherapy is combined with immunotherapy drugs (so-called checkpoint inhibitors such as nivolumab or pembrolizumab) before surgery. The goal is to activate the immune system to better attack the tumor. Recent studies (2026) compare this with standard chemoradiotherapy. Side effects can be serious and mainly involve inflammatory reactions in the body (for example, pneumonia, intestinal inflammation). This approach is not yet included in all guidelines as standard.
**Surgery (esophageal removal, esophagectomy)**
ProveniIncluded in official guidelines, or approved by EMA or FDA
The primary goal is to completely remove the tumor and remove nearby lymph nodes. The surgeon removes the affected part of the esophagus and then connects the stomach or colon to the healthy part of the esophagus so that food can pass through again. This is major surgery. Side effects in the period after surgery can include leakage from the new suture (anastomotic leakage), infections, and in the longer term reflux and swallowing disorders. Older patients have a higher chance of complications; doctors sometimes use geriatric screening tools to assess this. Nutritional support via a feeding tube around the time of surgery is also common.
**Chemotherapy + Radiation Alone (without surgery)**
ProveniIncluded in official guidelines, or approved by EMA or FDA
For certain patients who cannot be operated on (due to age, general condition, or personal preference), chemoradiotherapy may be the only treatment option. This offers less chance of complete cure, but can provide symptom relief and extend survival.
Advanced cancer (metastases in other organs or distant spread)
When cancer has spread, surgery is no longer an option. The focus is on extending life and relieving symptoms.
**Immunotherapy (checkpoint inhibitors)**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Medications such as nivolumab, pembrolizumab, and atezolizumab have now been approved for advanced esophageal cancer. They help the immune system better recognize and attack cancer cells. These medicines are usually given as a single agent, via infusion. Side effects include fatigue, skin rash, immune-related inflammation of various organs (lungs, intestines, liver), and rarely serious conditions. Not everyone responds to them; some patients develop resistance after initial success.
**Chemotherapy**
ProveniIncluded in official guidelines, or approved by EMA or FDA
For patients who are not eligible for immunotherapy, or as a first-line choice: combination chemotherapy (usually fluorouracil plus platinum). This inhibits cancer cell growth. Side effects include anemia, susceptibility to infection, nausea, fatigue, and mucus disorders. The effectiveness is usually temporary; after several months to years, the cancer may progress.
**Combination of chemotherapy and immunotherapy**
ResearchediPositive results in clinical studies, not yet standard treatment
This is being tested in clinical trials (2026). The idea is that chemotherapy and immunotherapy reinforce each other. Results appear promising in certain patient groups, but this is not yet standard.
**Targeted therapy against specific mutations**
ExperimentaliOngoing in study setting, outcome still unknown
For patients with certain inherited changes (mutations) in cancer cells, such as TP53 mutations, new targeted agents are being investigated in clinical trials. Examples are inhibitors that specifically target these genetic defects. These are not yet routinely available outside of trials.
**Anlotinib (in combination with chemoradiotherapy)**
ResearchediPositive results in clinical studies, not yet standard treatment
This medication inhibits blood vessel growth and immune responses. For certain situations (for example, cancer recurrence only in lymph nodes after initial treatment), it is being investigated in combination with chemoradiotherapy. Evidence is accumulating, but standard use is limited.
Supportive and symptom-relieving treatments
These are important regardless of the stage.
**Nutritional support**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Esophageal cancer and its treatment make eating difficult or impossible. A feeding tube (via the nose into the stomach, or surgically placed in the stomach or small intestine) ensures that patients still receive optimal nutrition. This helps maintain strength and speeds recovery from side effects. Possible risk: infections or discomfort from the tube.
**Pain management**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Esophageal cancer can cause severe pain. Doctors use a range of medications, from paracetamol to strong opioids, tailored to the severity. The goal is to maintain quality of life.
**Gastric acid suppression**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Many patients receive medications (proton pump inhibitors or H2 blockers) to reduce gastric acid, which reduces irritation and pain, especially if the esophagus is damaged by radiation or surgery.
---
_This information never replaces a doctor's judgment. Always discuss your situation with your own healthcare provider._